Dr. Damián García del Olmo
Dr. Damián García del Olmo
Head of Surgery at Jiménez Díaz Foundation University Hospital. Director of the Cell Therapy Unit at the Institute for Health Research at Jiménez Díaz Foundation University Hospital (IIS-FJD).
Clinical area
Surgeon Dr. García del Olmo is especially dedicated to conditions linked to colorectal cancer and proctology. He is a pioneer in the clinical use of stem cells to treat surgical procedures. His main medical and scientific activities focus on the development of advanced treatments for colorectal diseases, including innovative surgical approaches. He is currently researching the transformational capacity of nucleic acids in the plasma (Liquid Biopsy) of cancer patients (Genometastasis Theory).
Centros de los Médicos Dr. Damián García del Olmo
Internacional 2019: Centros a los que pertenezca un médico.
Professional experience
- Dr. Damián García Olmo obtained his PhD (1982) from the University of Murcia. He has over 25 years’ experience as a general surgeon, both in the clinical setting and in research. So far, he has personally performed over 6,000 surgical procedures in many fields of general surgery. His main medical and scientific activities focus on the development of advanced treatments for colorectal diseases, including innovative surgical approaches.
- Before its incorporation into the Jiménez Díaz Foundation, he was Head of Colorectal Surgery and the Director of the Cell Therapy Unit at La Paz University Hospital in Madrid.
Membership in scientific societies
- Member of many national and international scientific societies.
- President of the Spanish Coloproctology Association (2004-2005).
Research and teaching
- From 2002, Dr. García Olmo led a clinical trials process on the use of ASCs to treat complex perianal fistulae, with particular reference to Crohn’s disease patients, and his group led the first phase III clinical trial using mesenchymal stem cells. As a result of his research, he has developed five international patents in the field of regenerative medicine and two cell medications, which have opened two biotechnology companies. Furthermore, since 2008 his research has been cited in 2,400 studies, and he has developed an original theory about the possible infectious origin of colorectal cancer (currently only in vitro in animal studies).
Stay in foreign centers
- He has spent periods of complementary training at John Radcliffe Hospital in Oxford and St. Mark’s Hospital in London, as well as at Massachusetts General Hospital in Boston (USA).
Languages for clinical practice
- Spanish
- English
